Pharmacokinetic Study of A Systemically Administered Novel Liposomal Temoporfin Formulation in an Animal Tumor Model

Jenny Svensson,Ann Johansson,Niels Bendsoe,Susanna Grafe,Tilmann Trebst,Stefan Andersson-Engels,Katarina Svanberg
DOI: https://doi.org/10.1117/12.698932
2007-01-01
Abstract:Meso-tetra(hydroxyphenyl)chlorin (mTHPC) (international generic name Temoporfin) is a potent photosensitizer used for photodynamic therapy (PDT). In this study the pharmacokinetics of a systemically administered novel lipid formulation of Temoporfin in a murine tumor model has been investigated. Fluorescence spectroscopy measurements were performed at several time intervals following drug administration, yielding information on the Temoporfin concentration within excised internal organs as a function of time after injection. Both point-monitoring and imaging setups were used. The acquired fluorescence data were correlated to the concentration of Temoporfin obtained with High Performance Liquid Chromatography (HPLC). There was a significant correlation between the fluorescence methods and HPLC for most organs investigated. The pharmacokinetics of this new liposomal formulation of Temoporfin exhibited a rather flat temporal profile in the time interval 2-8 hours in this study.
What problem does this paper attempt to address?